| ID ▲ | Analyse | Domein | Recipiënt | Uitvoering | LTAT (uren (dagen)) | Accred. | LOINCeenheid (1) | LOINCeenheid (2) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 304 | Afp down + zwduur | Serum |
43 (1,8) | – | – | – | › | |||
| 351 | RhD-moleculair | EDTA |
166 (6,9) | – | – | – | › | |||
| 903 | FSH (M/V) | Serum |
– | – U/L | – | › | ||||
| 1270 | Factor II dosage | Citraat |
1× per 2 weken | – | 3289-6 % | – | › | |||
| 1272 | Factor V dosage | Citraat |
tenminste 1× per week | 218 (9,1) | – | 3193-0 % | – | › | ||
| 1274 | Factor VII dosage Proconvertine | Citraat |
1× per 2 weken | 521 (21,7) | – | 3198-9 % | – | › | ||
| 1292 | Factor XI dosage | Citraat |
1× per 2 weken | 422 (17,6) | – | 3226-8 % | – | › | ||
| 1294 | Factor XII dosage Hageman Factor | Citraat |
– | 3232-6 % | – | › | ||||
| 1296 | Factor XIII screening | Citraat |
– | 3239-1 | – | › | ||||
| 1342 | anti-factor Xa | Citraat |
1× per week | 96 (4) | – | 3216-9 IU/ml | – | › | ||
| 1343 | anti-Xa Rivaroxaban Anti-Xa (New Oral AntiCoagulants) | Citraat |
1× per week | – | 74871-5 ng/mL | – | › | |||
| 1344 | Anti-Xa Apixaban | Citraat |
maandag t/m vrijdag | 18 (0,7) | – | 74214-8 ng/mL | – | › | ||
| 1350 | Plaatjesfunctie | – | – | – | › | |||||
| 1369 | Bloedgroep + D (BTCA) | EDTA |
87 (3,6) | – | – | – | › | |||
| 1403 | LUTHERAN | EDTA |
– | – | – | › | ||||
| 1404 | Heredit. hemochromatose | EDTA |
– | – | – | › | ||||
| 1423 | Kp b antigeen (KEL4) | EDTA |
– | 1108-0 | – | › | ||||
| ● 1441 | Molec bep RhD variant | EDTA |
– | – | – | › | ||||
| 1449 | Mucoviscidose CF, CFTR, Cystic Fibrosis Transmembrane conductance Regulator-gen | EDTA |
724 (30,1) | – | – | – | › | |||
| 1451 | Fragile X syndroom FMR1, Fragile X Mental Retardation 1-gen | EDTA |
– | – | – | › | ||||
| 1459 | HLA-DQB1/DRB1 (narcolep) | EDTA |
1× per 2 weken | – | – | – | › | |||
| 1475 | DNA onderzoek A'pen | Heparine (Lithium-heparinebuis) (2×) EDTA (2×) |
6 (0,3) | – | – | – | › | |||
| 1476 | DNA onderzoek Leuven | Heparine (Lithium-heparinebuis) (2×) EDTA (2×) |
5 (0,2) | – | – | – | › | |||
| 1477 | DNA onderzoek VUB | Heparine (Lithium-heparinebuis) (2×) EDTA (2×) |
522 (21,8) | – | – | – | › | |||
| 1478 | DNA-onderzoek Gent | Heparine (Lithium-heparinebuis) (2×) EDTA (2×) |
– | – | – | › | ||||
| 1518 | Moleculaire bepaling RHCE | EDTA |
– | – | – | › | ||||
| 1550 | Fertiliteit Fertiliteitsonderzoek, Semen-onderzoek, Telling-Motiliteit-Morfologie | Sperma (Semen) |
197 (8,2) | – | – | – | › | |||
| 1553 | Vitaalkleuring | Sperma (Semen) |
8 (0,3) | – | – | – | › | |||
| 1555 | Morfologie | Sperma (Semen) |
197 (8,2) | – | 9704-8 | – | › | |||
| 1556 | Na vasectomie Semen-onderzoek postvasectomie | Sperma (Semen) |
18 (0,8) | – | – | – | › | |||
| 1575 | Voor capacitatie (AML) Semen-onderzoek voor proefcapacitatie | Sperma (Semen) |
127 (5,3) | – | – | – | › | |||
| 1577 | Na proefcapacitatie (AML) Semen-onderzoek na proefcapacitatie | Sperma (Semen) |
199 (8,3) | – | – | – | › | |||
| 1620 | Erythrocyten antistoffen Erythrocyten antistoffen - BTCA, Irreguliere antistoffen (identificatie), Rode bloedcel antistoffen - BTCA | Serum EDTA |
124 (5,2) | – | – | – | › | |||
| 1630 | Identificatie BTCA DAT, DCT, Directe Coombs - BTCA | EDTA |
47 (2) | – | – | – | › | |||
| 1640 | Elueren RBC antistof BTCA Elueren erythrocyten antistoffen - BTCA | EDTA |
– | – | – | › | ||||
| 1680 | Gluc-6-fosf.DH in RBC G6PD intraerythrocytair, Glucose-6-fosfaat dehydrogenase intraerythrocytair | EDTA |
tenminste 1× per week | 119 (4,9) | – | 2357-2 U/ml ery | – | › | ||
| 1683 | JAK2 V617F mutatie JAK2 mutatie, JAK2 mutation | EDTA |
1× per week | 424 (17,7) | – | – | – | › | ||
| 1684 | Pyruvaatkinase in RBC Pyruvaatkinase intraerythrocytair | EDTA |
459 (19,1) | – | 32552-2 U/g Hb | – | › | |||
| 1712 | MPN panel (12 genen) | EDTA |
1× per week | – | – | – | › | |||
| 1779 | Flowcytometrie ikv Immunofenotypering, Lymfocyten fenotypering | EDTA |
1 (0) | – | – | – | › | |||
| 1960 | PNH onderzoek FLAER expressie, Immunofenotypering (paroxysmale nachtelijke hemoglobinurie) | EDTA |
71 (3) | – | 55164-8 | – | › | |||
| 2000 | Dikdruppel controle | EDTA |
146 (6,1) | – | – | – | › | |||
| 2292 | Lange keten vetzuren | Serum |
– | 43677-4 | – | › | ||||
| 2293 | Famil.hyperlipidemie DNA apoB DNA, Familiale hypercholesterolemie, FH DNA | EDTA |
1× per 3 maanden | 221 (9,2) | – | – | – | › | ||
| 2295 | Fam. hypercholesterolemie | EDTA |
17 (0,7) | – | – | – | › | |||
| 2434 | CK iso-enzymen | Serum |
1× per maand | 969 (40,4) | – | 14680-3 U/l | – | › | ||
| 2592 | anti-IA2 antilichamen | Serum |
1× per maand | 909 (37,9) | – | 31209-0 U/mL | – | › | ||
| 2642 | Aminozuren kwantitatief | Heparine (Lithium-heparinebuis) |
2× per week | 303 (12,6) | – | 1913-3 | 35083-5 | › | ||
| 2655 | alfa Galactosidase | EDTA |
1× per week | 308 (12,9) | – | 1813-5 µmol/L/h | – | › | ||
| 2661 | Galactose | – | – | – | › |
